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Angiogenic and Osteogenic 
Synergy of Human Mesenchymal 
Stem Cells and Human Umbilical 
Vein Endothelial Cells Cocultured 
on a Nanomatrix
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To date, bone tissue regeneration strategies lack an approach that effectively provides an osteogenic 
and angiogenic environment conducive to bone growth. In the current study, we evaluated the 
osteogenic and angiogenic response of human mesenchymal stem cells (hMSCs) and green fluorescent 
protein-expressing human umbilical vein endothelial cells (GFP-HUVECs) cocultured on a self-
assembled, peptide amphiphile nanomatrix functionalized with the cell adhesive ligand RGDS (PA-
RGDS). Analysis of alkaline phosphatase activity, von Kossa staining, Alizarin Red quantification, and 
osteogenic gene expression, indicates a significant synergistic effect between the PA-RGDS nanomatrix 
and coculture that promoted hMSC osteogenesis. In addition, coculturing on PA-RGDS resulted in 
enhanced HUVEC network formation and upregulated vascular endothelial growth factor gene and 
protein expression. Though PA-RGDS and coculturing hMSCs with HUVECs were each previously 
reported to individually enhance hMSC osteogenesis, this study is the first to demonstrate a synergistic 
promotion of HUVEC angiogenesis and hMSC osteogenesis by integrating coculturing with the PA-
RGDS nanomatrix. We believe that using the combination of hMSC/HUVEC coculture and PA-RGDS 
substrate is an efficient method for promoting osteogenesis and angiogenesis, which has immense 
potential as an efficacious, engineered platform for bone tissue regeneration.
Bones not only provide support, but they also regulate blood pH, act as a mineral reservoir, generate hemato-
poietic stem cells, and produce mesenchymal stem cells1–3. Each year, delayed union and nonunion inhibit the 
healing process of 5–10% of the approximately 8 million incidences of bone fracture in the U.S. alone4. Due to the 
high importance of bone, finding strategies to aid in bone regeneration is vital. Currently, bone grafts are used as 
a standard clinical treatment for bone defects5. However, avascular bone grafts depend on diffusion for nutrient 
supply; therefore, large bone grafts often receive inadequate nutrition via diffusion, which leads to cell death5. 
Furthermore, resorption of the graft frequently occurs faster than osteogenesis. Autografts, in particular, are asso-
ciated with donor site morbidity, and allografts increase the risk of introducing infection or disease6. To overcome 
the inherent problems with grafts, an alternative approach to assist in the healing of critical-size bone defects is to 
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utilize a construct that mimics the natural bone microenvironment, which consists of inorganic hydroxyapatite 
crystals, organic protein fibers, osteogenic cells, and angiogenic cells7,8.
A bone analogous scaffold should contain components that not only promote osteogenesis but also foster 
angiogenesis to prevent hypoxia-induced cell death9. In bone tissue engineering, human mesenchymal stem 
cells (hMSCs) are commonly used as osteoprogenitor cells that can differentiate into osteoblasts and regenerate 
bone, and endothelial cells (ECs), often from umbilical veins, are used for angiogenesis. A main advantage of 
using hMSCs is that their endogenous production of angiogenic cytokines eliminates the need for the exogenous 
administration of therapeutic soluble factors that can induce angiogenesis in untargeted tissues, stimulate neo-
plastic growth, promote the development of abnormally functioning blood vessels, and increase atherosclerotic 
plaque mass10.
Because osteoprogenitor cells and ECs both play vital roles in bone regeneration, many studies have investi-
gated the effects of communication between these two cells on osteogenesis and angiogenesis11–21. For instance, 
it has been reported that in cocultures of hMSCs and ECs, direct cell-cell interactions and the paracrine effects 
induced by EC cytokines and regulatory molecules can enhance hMSC osteogenic differentiation15–17,22,23. 
Additionally, the Unger group showed that coculturing hMSC-derived osteoblasts with dermal microvascu-
lar ECs forms tissue-like structures with microcapillary-like networks18. Furthermore, Ma et al. demonstrated 
that the highest levels of osteogenic differentiation and angiogenesis are obtained in cocultures of hMSCs and 
human umbilical vein endothelial cells (HUVECs) at a cell ratio of 50:50 in differentiation medium17. Lastly, it 
was reported that hMSCs can stabilize EC-formed vascular structures in vivo and in vitro, inhibit EC apoptosis, 
and stimulate angiogenesis19,20.
Due to the mutual enhancements in osteogenesis and angiogenesis observed in hMSC/EC cocultures, inves-
tigating the effects of scaffold properties on osteogenesis and angiogenesis in cocultures has attracted much 
attention12. Notably, Kim et al. showed that coculturing hMSCs with HUVECs on nanotopography enhances 
hMSC osteogenesis more than culturing hMSCs alone on nanotopographical substrates or in coculture with ECs 
on flat substrates15. Stoppato et al. reported that enhanced osteogenic differentiation was observed in hMSC/
HUVEC cocultures on silk fibroin-free scaffolds compared with hMSCs cultured alone or on scaffolds with 
silk fibroin; in contrast, coculturing on silk fibroin-coatings promoted EC growth14. Furthermore, Guerrero’s 
group demonstrated that the combination of hMSC/EC coculture and 3D microenvironment—provided by a 
polysaccharide-based scaffold—favored hMSC osteogenesis21. In summary, each of these described tailored scaf-
folds has had substantial effects in stimulating either hMSC osteogenesis or HUVEC angiogenesis in cocultures.
Inspired by previous studies, in the current study, we introduced green fluorescent protein-expressing 
HUVECs (GFP-HUVECs), an angiogenic component, into hMSC cultures on a peptide amphiphile (PA-RGDS) 
nanomatrix. This addition of HUVECs helped us to develop an in vitro environment that more closely recapit-
ulates conditions which would be found in the future in vivo studies. In such in vivo studies, PA-RGDS, ECs, 
and hMSCs are expected to directly interact with one another. We investigated (1) the synergistic effects of the 
PA-RGDS nanomatrix and coculture with HUVECs on hMSC osteogenesis, and (2) the synergistic effects of the 
PA-RGDS nanomatrix and coculture with hMSCs on HUVEC angiogenesis.
As described in preceding literature, PA-RGDS nanomatrix contains a hydrophobic alkyl chain that is cova-
lently linked to two hydrophilic sequences: (1) the matrix metalloproteinase-2 (MMP-2) gene sequence, which 
promotes cell-driven scaffold degradation and fosters cell migration; and (2) the Arg-Gly-Asp-Ser (RGDS) 
sequence, a cell adhesion ligand, found naturally in fibronectin, through which the nanofibers mediate addi-
tional cell-extracellular matrix and cell-cell interactions24–26. Moreover, due to its amphiphilic nature, PA-RGDS 
can self-assemble into highly organized cylindrical nanofibers. At a higher order level, PA-RGDS nanofibers 
intertwine to form a nanomatrix, which mimics the organic structural component of the extracellular matrix 
(ECM)27–30. Previously, we showed that in both growth and differentiation media, the PA-RGDS nanomatrix can 
increase osteogenic differentiation of hMSCs into osteoblasts28–30. Incorporating hydroxyapatite nanoparticles 
into the PA-RGDS nanomatrix can yet further promote hMSC osteogenic differentiation30.
Therefore, here, we expected that cocultures on PA-RGDS nanomatrix would synergistically promote osteo-
blastic differentiation and HUVEC angiogenesis. More specifically, we hypothesized that: (1) the coculture with 
hMSCs and the PA-RGDS nanomatrix would amplify the angiogenic response of HUVECs compared to their 
monoculture or coculture on the standard negative control, plasma-treated tissue culture plates (TCPs); and (2) 
hMSCs in coculture with HUVECs on PA-RGDS would show a greater osteogenic response than any other exper-
imental group (Fig. 1). To address our hypotheses, PA-RGDS nanomatrix substrates were prepared first. Then, 
hMSC/GFP-HUVEC cocultures were maintained on PA-RGDS. The hMSC monocultures and GFP-HUVEC 
monocultures on PA-RGDS nanomatrix as well as the hMSC monocultures, GFP-HUVEC monocultures and 
hMSC/GFP-HUVEC cocultures on TCP were prepared as controls for comparison. Osteogenesis of hMSCs 
was evaluated by analyzing gene and protein expression as well as staining and quantifying calcium deposition. 
Angiogenesis by GFP-HUVECs was investigated by analyzing the gene and protein expression and by imaging 
GFP-HUVEC network formation. To the best of our knowledge, this is the first study that demonstrated the 
synergistic effects of cell-cell and cell-PA-RGDS interactions on hMSC osteogenesis and HUVEC angiogenesis.
Results and Discussion
Alkaline phosphatase assay. ALP is considered an early marker of osteoblastic differentiation31,32. It is 
widely used to detect osteoblasts because an increase in ALP activity can signify the start of new bone formation 
by these cells. During the differentiation process, ALP activity within cell cultures will increase when organic 
phosphates are cleaved to create free, inorganic phosphates for use in mineralization33. Enhanced expression of 
ALP occurs during ECM maturation, which precedes mineralization34,35.
Figure 2 shows the ALP activity measured in cultures at days 1, 7, 14, and 28. Because ALP is produced by 
osteogenic cells, observed ALP activity in cocultures is attributed to hMSCs and not HUVECs. Importantly, at 
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days 7 and 14, hMSCs in cocultures generally showed slightly greater ALP activity compared to their monocul-
tured counterparts. The respective ALP levels from hMSCs cocultured and monocultured on TCPs at day 7 were 
0.011 ± 0.0006 and 0.008 ± 0.002 μg of ALP per μg of DNA. The ALP from hMSCs cocultured and monocultured 
on TCPs then increased at day 14 to 0.038 ± 0.005 and 0.032 ± 0.003 μg of ALP per μg of DNA, respectively. The 
enhanced osteogenesis that resulted from the coculture condition is in agreement with previous studies22,36,37. 
For instance, Hasirci’s group showed that cocultures of rat bone marrow stem cells and rat aortic endothelial 
cells exhibited more ALP activity than either cell in monoculture22. The addition of PA-RGDS yet further ampli-
fied ALP activity; cocultured hMSCs on PA-RGDS exhibited ALP activity at day 7 (0.016 ± 0.002 μg ALP per 
μg of DNA) and day 14 (0.059 ± 0.004 μg of ALP per μg of DNA) that was significantly greater than the ALP 
activity of any other condition at the same timepoints. Interestingly, the ALP activity for cocultured hMSCs on 
PA-RGDS progressively increased from day 1 to day 14 but significantly decreased by day 28. A similar result 
was also demonstrated by Ma et al., in which the highest ALP activity in hMSC/HUVEC cocultures occurred on 
day 14 with a cell ratio of 50:5017. However, the ALP activity for monocultured hMSCs continuously increased 
throughout the incubation period, and the highest ALP activity (0.046 ± 0.00015 μg of ALP per μg of DNA) was 
observed at day 28. A promising result, the earlier and greater ALP activity in the PA-RGDS cocultures signifies 
not only increased osteogenesis, but a more rapid overall differentiation process38,39. In addition, at day 28, the 
ALP activity of hMSC monocultures on PA-RGDS was higher than that of hMSC monocultures on TCPs which 
also agrees with our previous reported data28. Overall, the data indicate that PA-RGDS combined with the cocul-
ture condition synergistically promotes greater osteogenic differentiation of hMSCs than other conditions in the 
current study.
Mineralization analysis via Alizarin Red quantification and von Kossa staining. When osteo-
genic cells start to differentiate into osteoblasts, they begin to secrete mineral deposits35. Therefore, high mineral 
accumulation in the ECM usually indicates complete osteogenic differentiation of osteoblasts. In addition, ALP 
Figure 1. Schematic of the experimental strategy. Included are the expected synergistic effects on osteogenesis 
and angiogenesis of hMSCs and GFP-HUVECs cocultured on a peptide amphiphile nanomatrix functionalized 
with the RGDS motif.
Figure 2. ALP activity at days 1 and 7 (a) and days 14 and 28 (b) post cell-seeding. Samples were normalized 
by total DNA content observed in the Picogreen assay. Values are expressed as a mean ± standard error of 
measurement (**p = 0.01).
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activity has a significant role in initiating mineralization. Since the synergistic promotion of osteogenic differenti-
ation of hMSCs by combining coculture and PA-RGDS was observed earlier, we next investigated the mineraliza-
tion degree in the six groups of interest after a 21-day culture period using the Alizarin Red quantification kit. The 
Alizarin Red quantification for calcium deposition shows that mineralization induced by coculture and PA-RGDS 
was significantly higher than that of the other studied groups (Fig. 3a). The intensity of the absorbance of Alizarin 
Red in the coculture on PA-RGDS, coculture on TCP, monoculture on TCP and monoculture on PA-RGDS 
are 0.65 ± 0.04, 0.50 ± 0.03, 0.32 ± 0.014, and 0.42 ± 0.03, respectively (Fig. 3a). A comparable result was also 
observed in Alizarin Red quantification after 28-day culture: the mineralization resulting from the coculture 
and PA-RGDS achieved the highest calcium deposits among all the studied groups (see Supplementary Fig. S1).
Moreover, to better visualize the mineralization degree, we characterized the extent of mineralization in the 
groups after a 28-day culture period using von Kossa staining. The reason we chose von Kossa staining is that 
calcium deposits stained by von Kossa staining are easier to observe than those stained by Alizarin red staining. 
As seen in Fig. 3b–g, the von Kossa staining results agree well with the result observed in Alizarin Red quantifica-
tion. Specifically, von Kossa staining for calcium shows that cocultures contained a larger mineralized area with 
more mineral deposition than monocultures. In addition, hMSCs on PA-RGDS displayed greater mineralization 
than those on TCPs. This observation indicates the improved osteoconductive and osteoinductive potential of 
PA-RGDS cultures due to cell interactions with the RGDS ligand sequence (found in numerous ECM proteins), 
which may have triggered specific differentiation cues via cell-ECM interactions29,40,41. Moreover, the RGDS cell 
adhesion moiety has been shown to enhance osteoblast cell attachment and spreading, as well as induce miner-
alization42–44. Notably, cocultures on PA-RGDS exhibited the greatest degree of mineralization, as revealed by 
the larger stained area of mineral deposits. This result is consistent with the data collected from the ALP assay 
and further supports that osteogenesis is significantly enhanced when hMSCs are cocultured with HUVECs on 
PA-RGDS. Furthermore, Grellier et al. observed a similar result in an earlier study in which mineralization was 
more extensive when osteoprogenitors were cocultured with endothelial cells, rather than monocultured, and 
when both cells were immobilized on RGD-grafted alginate microspheres45,46. As previously mentioned, the peak 
ALP activity in cocultured hMSCs on PA-RGDS was observed at day 14, signifying that the differentiation pro-
cess had begun prior to this day. During cell differentiation, peak ALP activity occurs before mineralized matrix 
formation, as ALP promotes mineralization34,35. Therefore, we speculate that mineralization started in PA-RGDS 
Figure 3. Day 21 Alizarin Red Quantification (a). Day 28 von Kossa staining. Row 1: PA-RGDS (b–d), and 
Row 2: TCP (e–g). Column 1: hMSCs (b,e), Column 2: HUVECs (c,f), Column 3: Coculture (d,g). Red staining 
shows locations of calcium deposits.
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cocultures before other cultures. As shown in von Kossa staining images and Alizarin red quantification, accel-
erated initiation of the mineralization process in the PA-RGDS cocultures resulted in the greatest amount of 
mineral accumulation on both day 21 and day 28.
Osteogenic and angiogenic gene expression and protein secretion. In addition to ALP activity 
and mineralization, the gene expressions of several crucial osteogenic markers were quantified for all samples at 
7, 14, and 21 days post cell-seeding. Analyzed osteogenic gene markers included runt-related transcription factor 
2 (Runx2), bone morphogenic protein-2 (BMP-2), ALP, and osteocalcin (OCN). During the well-orchestrated 
process of hMSC differentiation into osteoblasts, these genes, which are indicative of osteogenic phenotypes, are 
upregulated in a specific sequence. Thus, they are considered established markers of osteoblastic development47.
ALP gene expression was investigated first. As seen in Fig. 4a, on days 7 and 14, ALP gene expression was sig-
nificantly upregulated in PA-RGDS cocultures as compared to other cultures. Upregulation of ALP in PA-RGDS 
cocultures helps explain the enhanced mineralization and ALP content in these cultures. As an early marker for 
osteogenesis, ALP gene expression peaked on day 14 in the PA-RGDS cocultures at a higher value than in all other 
cultures which signifies the heightened osteogenic potential of this test group. Though, on days 7 and 14, hMSC 
monocultures on PA-RGDS showed enhanced ALP gene expression compared to monocultures on TCPs gene 
expression was not as pronounced as that seen in PA-RGDS cocultures. In previous studies, endothelial cell and 
hMSC cocultures showed similar early upregulation of ALP expression compared to hMSC monocultures16,36,48,49. 
However, as seen in this study, PA-RGDS promotes even higher levels of early ALP gene expression. Moreover, a 
downregulation of ALP gene expression was observed on day 21 in cocultures on PA-RGDS nanomatrix, which 
further suggests that PA-RGDS nanomatrix combined with coculture can accelerate the osteogenic differentiation 
of hMSCs in coculture. This downregulation might be attributed to the development of an osteoid matrix around 
osteoblasts as mineralization progressed47.
Secondly, Runx2 gene expression was analyzed. Runx2 is the earliest transcriptional regulator necessary for 
bone formation and is also an essential mediator of osteoblast differentiation50,51. Seen in Fig. 4b, significant 
differences in Runx2 gene expression were not observed between any of the culture groups on day 7. A similar 
result was reported by Xue et al., in which coculturing hMSCs with HUVECs did not significantly increase their 
expression of Runx2 after 5 days of incubation compared with Runx2 gene expression in hMSC monocultures16. 
However, on day 14, coculturing substantially enhanced Runx2 gene expression as compared to that in hMSC 
monocultures. Similarly, Bidarra et al. also showed that Runx2 gene expression is upregulated in cocultures com-
pared to monocultures on TCP36. Importantly, Runx2 gene expression in PA-RGDS cocultures was upregulated 
at day 14 more than all other cultures at that timepoint. This upregulation indicates that the RGDS cell adhe-
sion ligand, coupled with the coculturing condition, can promote and accelerate Runx2 gene expression, lead-
ing to earlier phenotypic commitment of hMSCs to osteogenic differentiation. In addition, a decrease of Runx2 
gene expression in PA-RGDS cocultures was seen on day 21. The interesting observation may be ascribed to the 
function and osteogenic cell source of Runx2; it is a transcription factor that increases the number of imma-
ture osteoblasts, which is strongly expressed by preosteoblasts and immature osteoblasts but downregulated by 
mature osteoblasts52,53. Thus, the observed upregulated expression of Runx2 on day 14 in cocultures on PA-RGDS 
indicates that a high number of hMSCs had differentiated into preosteoblasts and immature osteoblasts, but the 
subsequent downregulation supports the conclusion that most of these osteogenic cells had fully matured into 
osteoblasts by day 21.
Runx2 regulates the expression of bone matrix protein genes—including OCN—during osteoblast differen-
tiation52. Since an upregulation of Runx2 in PA-RGDS cocultures was observed, next we investigated OCN gene 
expression, which is regarded as an established late marker for osteoblast differentiation that appears concom-
itantly with the mineralization phase of bone formation47. As seen in Fig. 5a, the OCN gene expression at day 
Figure 4. ALP (a) and Runx2 (b) gene expression. Gene expression is shown for monocultures and cocultures 
on TCPs and PA-RGDS at days 7, 14, and 21, as expressed as fold ratios relative to gene expression of hMSC 
monocultures on TCPs at day 7. Data, provided as mean ± standard deviation, are normalized to GAPDH gene 
expression (**p < 0.05 and ***p < 0.005).
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14 for monocultures and cocultures on PA-RGDS was almost 3.5 times higher than its counterparts on TCPs, 
indicating that PA-RGDS can promote OCN gene expression However, on day 14, we did not see a synergistic 
effect on gene expression produced by the combination of coculturing and PA-RGDS. Moreover, on day 21, sig-
nificant downregulations of OCN gene expression were observed in monocultures and cocultures on PA-RGDS; 
conversely, an upregulation in OCN gene expression was observed in TCP monocultures and cocultures on day 
21, indicating a prolonged delay in osteoinduction compared to that of cultures on PA-RGDS. Thus, PA-RGDS 
appears to be the most potent factor that fosters accelerated OCN expression. However, on day 21, coculturing 
upregulated gene expression on TCPs compared to monoculturing. As OCN is highly expressed by mature oste-
oblasts, the accelerated upregulation of OCN gene expression observed on PA-RGDS cultures at day 14 suggests 
that more hMSCs had terminally differentiated by this timepoint than those on TCPs47,52. The subsequent down-
regulation of gene expression observed in the PA-RGDS cultures at day 21 may have been a result of mature oste-
oblasts becoming osteocytes and embedding in the ECM they secreted47,52. Compared to days 7 and 14, amplified 
OCN gene expression in TCP cultures at day 21 may be indicative of an increased number of mature osteoblasts, 
which had not yet become embedded osteocytes.
BMP-2 gene expression is shown in Fig. 5b. Compared with hMSC monocultures on TCPs, an earlier upreg-
ulation of BMP-2 was seen in response to the coculture condition and the PA-RGDS substrate. On day 7, the 
combination of coculture and PA-RGDS amplified the expression of the BMP-2 gene more than the PA substrate 
alone. However, at day 14, BMP-2 gene expression was the most pronounced in cocultures on TCPs. By day 21, 
cocultures on PA-RGDS displayed the most enhanced BMP-2 gene expression, which was, on average, more than 
50 times higher than hMSC monocultures on TCPs at day 7 As one of the most readily detectable BMPs in osteo-
genic cultures, BMP-2 promotes the differentiation of mesenchymal progenitor cells into osteoblasts47. Moreover, 
BMP-2 is the most powerful inducer of bone formation in vivo. Studies have demonstrated that high doses of 
BMP-2 will initiate earlier bone formation in osteogenic cultures54. BMP-2 gene expression is upregulated early 
in the process of bone development and, as a signaling molecule, facilitates the expression of Runx2 and ALP in 
osteoprogenitor cells47,55. Therefore, the earlier upregulation at day 7 of BMP-2 gene expression in cocultures on 
PA-RGDS may signify an accelerated initiation of hMSC osteogenic differentiation in contrast with other cul-
tures. The second upregulation of BMP-2 at day 21 suggests that there was higher potential for bone formation in 
cocultures on PA-RGDS than in other test groups.
The expression of vascular endothelial growth factor (VEGF) correlates with osteoblastic differentiation. 
VEGF gene expression is low when osteoblastogenesis begins, it increases in parallel with OCN expression dur-
ing terminal differentiation, and it peaks during mineralization56. Thus, VEGF is an osteogenic marker. As shown 
in Fig. 6a, on day 14 and day 21, cocultures on PA-RGDS exhibited substantially greater expression than all other 
culture conditions. On day 21, VEGF gene expression in cocultures on PA-RGDS was almost 10 times higher 
than that in TCP cocultures, and it was almost 15 and 12 times higher than HUVEC and hMSC monocultures 
on PA-RGDS, respectively. In addition, on day 21, cocultures on TCPs had slightly higher VEGF gene expres-
sion than hMSC monocultures on TCPs, which agrees with a former study that demonstrated that coculturing 
osteoprogenitor cells with HUVECs can result in higher VEGF gene expression than that seen in monocultures57. 
Taken together, these data indicate that the coculture condition and PA-RGDS substrate can significantly promote 
the osteogenesis of hMSCs46. The enhancement of VEGF gene expression observed here may also explain the 
elevated level of ALP activity in the PA-RGDS cocultures on day 14, as observed using the ALP assay58.
We also investigated the degree of VEGF secretion using enzyme-linked immunosorbent assay. Significantly, 
on day 21, the synergistic enhancement of VEGF secretion resulting from PA-RGDS and coculture was promi-
nent, as demonstrated by the result that the secreted VEGF amount in the coculture on PA-RGDS was the highest 
(Fig. 6b). The greatest VEGF production at day 21 in coculture on PA-RGDS compared to other groups may be 
Figure 5. OCN (a) and BMP-2 (b) gene expression. Gene expression is shown for monocultures and 
cocultures on TCPs and PA-RGDS at days 7, 14, and 21 post cell-seeding, as expressed as fold ratios relative to 
gene expression of hMSC monocultures on TCPs at day 7. Data are normalized to GAPDH gene expression 
(**p < 0.05 and ***p < 0.005).
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ascribed to the greatest gene upregulation of VEGF in this group at day 14 an day 21 (Fig. 6a). More importantly, 
VEGF secreted by osteoblasts/osteocytes has high angiogenic power, as it serves as a paracrine factor that pro-
motes endothelial cell proliferation. Indeed, a previous study reported that VEGF-secreting osteoblastic cells, 
derived from hMSCs, increased the proliferation of HUVECs59. Thus, VEGF is also used as an angiogenic marker. 
Therefore, the augmented VEGF gene expression and protein secretion in PA-RGDS cocultures at day 21 indicate 
that the hMSCs reached an elevated level of osteogenic differentiation and were expected to stimulate more angi-
ogenesis in this culture group than in any other test groups.
Network formation imaging. To check our hypothesis that increased VEGF gene expression and pro-
tein secretion would increase angiogenesis, we imaged the morphology of HUVECs and the extent of HUVEC 
network formation in each culture group. By day 7 post cell-seeding, HUVEC/hMSC cocultures on PA-RGDS 
showed aggregation and alignment of endothelial cells, as well as extensive pseudopodia formation character-
istic of the vascular morphogenetic process (Fig. 7a). Cocultures on TCP did not display the same degree of 
extending pseudopodia as that seen in cocultures on PA-RGDS. By day 14, network formation, as indicated 
by further aggregation, spreading, and branching, was quite apparent in PA-RGDS cocultures (Fig. 7b). Cell 
elongation progressed slightly by day 21 in these cocultures (Fig. 7c). At day 14, cocultures on TCP showed 
considerate cell spreading but much less coalescence than cocultures on PA-RGDS (Fig. 7e). However, by day 
21, the cell aggregation in TCP cocultures was much more reminiscent of that seen in PA-RGDS cocultures 
(Fig. 7f). In contrast to the cocultures, HUVEC monocultures showed much less vascular network formation. 
Nevertheless, PA-RGDS monocultures outperformed monocultures on TCPs. For instance, at day 14, HUVEC 
monocultures on PA-RGDS displayed some pseudopodia formation and cell clustering. However, from day 
14 to day 21, vascular morphogenesis did not seem to progress. HUVECs in monocultures on TCPs showed 
little to no clustering and cell spreading throughout the duration of the study but remained relatively round 
and separated.
It has previously been reported by Issaragrisil’s group that the cytokines insulin-like growth factor 1, stromal 
cell-derived factor 1, and VEGF—all of which are secreted by hMSCs—can promote HUVEC vessel formation60. 
Thus, the accelerated endothelial cell spreading, aggregation, alignment and network formation in cocultures 
on PA-RGDS indicates that cell-cell interactions between osteogenic and endothelial cells are vital to promote 
vascular network formation, which may be further enhanced through interactions with the cell adhesion ligand 
RGDS provided by the functionalized PA.
In conclusion, we used ALP assay, von Kossa staining, Alizarin Red staining, analysis of osteogenic and 
angiogenic gene expression and related protein content, and characterization of endothelial cell network for-
mation to evaluate the synergistic effects of PA-RGDS nanomatrix and coculturing hMSCs with HUVECs 
on hMSC osteogenesis and HUVEC angiogenesis. As compared to monocultures and all cultures on TCPs, 
the PA-RGDS nanomatrix and coculture condition synergistically enhanced ALP activity, mineralization 
character, and most of the studied osteogenic gene expression by hMSCs. Moreover, upregulated VEGF gene 
expression and increased VEGF secretion as well as network-like structures were observed in cocultures on 
PA-RGDS, hinting at a synergy between hMSCs and HUVECs and PA-RGDS that improved angiogenesis. 
The results of the current study clearly suggest that the PA-RGDS nanomatrix, combined with the beneficial 
cell-cell crosstalk in HUVEC/hMSC cocultures, offers a promising biomimetic solution for bone tissue engi-
neering that provides an angiogenic and osteogenic environment with the potential to stimulate, and even 
accelerate, bone healing and growth.
Figure 6. VEGF gene expression (a) and accumulative VEGF secretion (b). Gene expression is displayed 
for cultures on days 7, 14, and 21 as a fold ratio relative to HUVEC monocultures on TCP at day 7. Data are 
expressed as mean ± standard deviation and are normalized to GAPDH gene expression (**p < 0.05 and 
***p < 0.005).
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Methods
PA-RGDS synthesis. Similar to previously described methods of peptide synthesis, PA-RGDS was syn-
thesized in an Advanced Chemtech Apex 396 peptide synthesizer at a 0.30 mmol scale using standard Fmoc-
chemistry28,61. The PA was alkylated by reacting N-termini of the peptides with 2 equivalents of palmitic acid, 2 
equivalents of o-benzotriazole-N,N,N′,N′ tetramethyluroniumhexafluorophosphate, and 4 equivalents of diiso-
propylethylamine in dimethylformamide for 3 hours at room temperature. After repeating the alkylation reac-
tion once more, cleavageand deprotection of PA-RGDS were performed through gentle mixing in a solution of 
trifluoroacetic acid (TFA), deionized (DI) water, and triisopropylsilane at the ratio of 38:1:1 for 1 hour at room 
temperature. The resulting solution was filtered from the resin, which was rinsed with 2 additional milliliters of 
TFA. The collected flow-through was rotoevaporated for further removal of impurities, and the PA was precipi-
tated out of solution using cold ether. The precipitate was lyophilized for 48–72 hours.
PA-RGDS nanomatrix. A 0.1 wt% stock solution of PA-RGDS was prepared in DI water and adjusted to 
pH 7.4 through the controlled addition of NaOH. For the alkaline phosphatase assay and von Kossa staining 
experiments, 200 uL of PA-RGDS stock solution were then placed in each well of 48-well TCPs. For the PCR 
experiments, 1 mL of PA-RGDS stock solution was placed in each well of 6-well TCPs. For Alizarin Red quantifi-
cation as well as VEGF secretion study, 400 ul of PA-RGDS stock solution was placed in each well of 24-well TCPs. 
To evaporate the solvent and induce PA-RGDS self-assembly, the plates were placed in a biosafety cabinet for 24 
hours and UV-sterilized for an additional 1.5 hours.
Cell culture. hMSCs (Lonza, Walkersville, MD), isolated from bone marrow, were cultured in Mesenchymal 
Stem Cell Growth Medium. GFP-HUVECs (Angioproteomie, Boston, MA) were cultured in Endothelial Basal 
Medium (EBM) supplemented with the Endothelial Growth Medium-2 (EGM-2) SingleQuots kit. Each of these 
cell types were cultured in T-75 flasks (Corning Inc., Corning, NY) at standard culture conditions of 37 °C, 95% 
humidity, and 5% carbon dioxide. When confluent, the cells were passaged using 0.05% trypsin and then seeded 
in TCPs. The seeded cells were cultured at the previously described standard conditions. During both cell expan-
sion and plate culture, media was replaced every 2 to 3 days.
For all experiments, the following conditions were used: PA-RGDS nanomatrix substrates, used for exper-
imental groups, and TCPs, used for control groups. On each substrate, 3 cell-seeding conditions were used: 1) 
hMSCs in monoculture, 2) GFP-HUVECs in monoculture, and 3) hMSCs cocultured with GFP-HUVECs. In 
Figure 7. GFP-expressing HUVECs, indicating extent of network formation. Images are shown for HUVEC/
hMSC cocultures on PA-RGDS (a–c) and on TCPs (d–f) and for HUVEC monocultures on PA-RGDS (g–i) and 
on TCPs (j–l). Fluorescent images show progression of vascular morphogenesis at days 7 (a,d,g,j), 14 (b,e,h,k), 
and 21 (c,f,i,l) post cell-seeding.
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monocultures used for the alkaline phosphatase assay and von Kossa staining, 13,500 GFP-HUVECs or hMSCs 
were seeded per well. In cocultures, 13,500 hMSCs and HUVECs were each seeded per well, yielding a combined 
total of 27,000 cells per well of the 48-well plates. For Alizarin Red quantification as well as VEGF secretion study, 
25,000 GFP-HUVECs or hMSCs were seeded per well. In cocultures, 25,000 hMSCs and HUVECs were each 
seeded per well, yielding a combined total of 50,000 cells per well of the 24-well plates. Six repetitions were used 
for each condition.
In the GFP-HUVEC and hMSC monocultures used for qRT-PCR experiments and network formation imag-
ing, 80,000 cells were seeded per well. For cocultures, 80,000 hMSCs and GFP-HUVECs were each seeded per 
well, equaling a total of 160,000 cells per well of the 6-well plates. Each condition was repeated in quadrupli-
cate. After cell seeding, a 1:1 volume ratio of osteogenic differentiation medium and endothelial cell growth 
medium was added to each well for cell culture. The osteogenic differentiation medium was made of a basal 
medium and an hMSC Osteogenic SingleQuots kit (Lonza, Walkersville, MD) that contained the following sup-
plements: 0.5% dexamethasone, 0.5% ascorbate, 10% meningeal cell growth supplement, 2% L-glutamine, 1% 
penicillin-streptomycin, and 1% B-glycerophosphate. The endothelial cell growth medium consisted of EBM 
supplemented with the EGM-2 SingleQuots kit, which contained the following supplements: 2% fetal bovine 
serum, 0.04% hydrocortisone, 0.4% human fibroblast growth factor-B, 0.1% VEGF, 0.1% R3 insulin like growth 
factor-1, 0.1% ascorbic acid, 0.1% human epidermal growth factor, 0.1% GA-1000 (gentamicin, amphotericin-B), 
and 0.1% heparin (Lonza, Walkersville, MD).
Alkaline phosphatase assay. Cells were harvested with trypsin at 1, 7, 14, and 28 days and stored in 
Eppendorf tubes at −80 °C until they were retrieved for analysis. An ALP fluorometric assay (Abcam, Cambridge, 
MA) was used to measure the amount of ALP from each sample. Specifically, 60 μL of cell lysate, 60 μL of alkaline 
buffer, and 100 μL of phosphatase substrate solution were added to each well of a 96-well plate and incubated 
for 1 hour at 37 °C. Standards in known concentrations ranging from 0 μM to 1,000 μM were prepared using 
p-nitrophenol and added to designated wells in the same plate. After incubating for 1 hour, the kinase reac-
tion was stopped by adding 100 μL of 0.3 M NaOH to each well. Absorbances were measured at 405 nm using 
a microplate reader (Synergy HT, BIO-TEK Instruments, Winooski, VT) and then compared to standards with 
known ALP content. Results were normalized to the total cell number at each timepoint, as measured by the 
PicoGreen DNA Assay (Molecular Probes, Eugene, OR). More precisely, Picogreen Dye from the assay kit was 
added to prepared samples, which were incubated in the dark for 15 minutes. The amount of DNA was then 
measured using a fluorescence microplate reader and was compared to prepared standards with known DNA 
content. Finally, ALP results were normalized to measured DNA content.
Von Kossa staining. After 28 days, cells were fixed with 10% formalin according to the manufacturer’s pro-
tocol (Abcam, San Francisco, CA). Stained cells were imaged using color brightfield microscopy.
Alizarin Red staining and quantification. After 21 and 28 day culture, Alizarin Red quantification was 
conducted through the Alizarin Red Quantification Assay (ScienCell, Carlsbad, CA) according to the manufac-
turer’s protocol using a microplate reader (Synergy HT, BIO-TEK Instruments, Winooski, VT).The absorbance 
was measured at 405 nm.
qRT-PCR. At days 7, 14, and 21, GFP-HUVECs and hMSCs were collected and lysed using RNeasy Plus Mini 
Kit (Qiagen, Hilden, Germany). RNA from the cells was isolated according to the manufacturer’s protocol. RNA 
was suspended in nuclease free water, and an ND-1000 UV spectrophotometer (Nanodrop, Wilmington, DE) was 
used to quantify the concentration of RNA for each sample. Complementary DNA was then synthesized using 
500 ng of RNA, which was reverse transcribed in a 2720 Thermo Cycler (Applied Biosystems, Foster City, CA) 
using a Verso cDNA Synthesis Kit (Thermo Fisher Scientific, Waltham, MA) according to the manufacturer’s 
protocol. Samples were prepared in a 96-well PCR plate using the TaqMan Master Mix protocol. Each sample 
consisted of 2 µL of cDNA solution, 10 µL of 2x master mix, 7 µL of RNA-free water, and 1 µL of gene primer 
(Runx2, BMP-2, ALP, OCN, VEGF, or GAPDH gene primer) from a TaqMan Gene Expression Assay kit (Applied 
Biosytems, Foster City, CA). The PCR plate was run in a LightCycler 480 (Roche Life Science, Indianapolis, IN) 
for the following cycles: pre-incubation at 50 °C for 2 minutes and 95 °C for 10 min; amplification for 45 cycles, at 
95 °C for 15 seconds and 60 °C for 1 minute during each cycle; melting at 95°C for 5 seconds and 65 °C for 1 min-
ute; and cooling at 40oC for 30 seconds. Runx2, BMP-2, ALP, and OCN gene amplifications were used to evaluate 
osteogenic gene expression. VEGF pathway gene amplification was used to evaluate angiogenic gene expression. 
Gene expression was normalized against the housekeeping gene, GAPDH. As described in a previous study, the 
2−ΔΔCT method was used to assess gene expression29. For Runx2, BMP-2, ALP, and OCN gene expression, data 
at each timepoint is expressed as a fold ratio relative to data acquired for the hMSC monoculture on TCP at day 
7. VEGF gene expression at each timepoint is shown as a fold ratio relative to the GFP-HUVEC monoculture on 
TCP at day 7.
Evaluation of VEGF secretion. To measure the amount of secreted VEGF from the six groups of interests, 
enzyme-linked immunosorbent assay (ELISA; R&D system, MN, USA) was conducted. Supernatant from the 
samples was collected every other day, and the accumulative secretion of VEGF on day 7, 14 and 21 were analyzed 
by sandwich ELISA method using a microplate reader (Synergy HT, BIO-TEK Instruments, Winooski, VT). The 
absorbance was measured at 450 nm.
Network formation imaging. Using fluorescence microscopy, GFP-HUVECs were imaged at 7, 14, and 21 
days post cell-seeding to assess the extent of cell spreading, alignment, and aggregation.
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Statistical analyses. Presented data are representative of experimental results. Each experiment was per-
formed at least three independent times with conditions repeated in quadruplicate at each timepoint. Values are 
expressed as mean ± standard deviation. To assess significance between data, Student’s t test or one-way analysis 
of variance (ANOVA) and post hoc analysis using Tukey’s range test for multiple comparisons were conducted. 
For all tests, p < 0.05 is considered statistically significant. p < 0.005 is considered extremely statistically signif-
icant. Moreover, the p values for Fig. 3a are summarized in Supplementary Table S1. The p values for Figs 4–5 
are summarized in Supplementary Table S2. The p values for Fig. 6 are summarized in Supplementary Table S3.
Data Availability
The datasets generated during the current study are available from the corresponding author on reasonable re-
quest.
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